STOCK TITAN

Windward Bio IPO: OrbiMed fund buys 1.18M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Windward Bio Group AG (WWB) reports transactions involving shares held by OrbiMed Private Investments IX, LP (OPI IX), in a joint report by OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC. On November 16, 2026, OPI IX purchased 1,176,471 common shares at $17 per share in the initial public offering. Its Series A and B preferred shares automatically converted one-for-one into 3,561,936 and 1,611,008 common shares immediately before the offering closed. OPI IX also exercised warrants for 216,668 common shares at $0.02 each; the report records 232 common shares delivered or withheld for payment of exercise price or tax liability in connection with the warrant exercise.

Insider ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC
Role Director, 10% Owner | Director, 10% Owner
Bought 1,176,471 shs ($20.00M)
Increase in Position 221.3%
Type Security Shares Price Value
Conversion Series A Preferred Shares F4, F2, F3 3,561,936 $0.00 $0.00
Conversion Series B Preferred Shares F4, F2, F3 1,611,008 $0.00 $0.00
Exercise Warrants (right to buy) F5, F7, F2, F3 216,668 $0.00 $0.00
Purchase Common Shares F1, F2, F3 1,176,471 $17.00 $20.00M
Conversion Common Shares F4, F2, F3 3,561,936 -- --
Conversion Common Shares F4, F2, F3 1,611,008 -- --
Exercise Common Shares F5, F2, F3 216,668 $0.02 $4K
Exercise Price or Tax Liability Common Shares F6, F2, F3 232 $17.00 $4K
Holdings After Transaction: Series A Preferred Shares — 0 shares (Indirect, See footnotes); Series B Preferred Shares — 0 shares (Indirect, See footnotes); Warrants (right to buy) — 0 warrants (Indirect, See footnotes); Common Shares — 7,097,483 shares (Indirect, See footnotes)
Holdings Before and After: Series A Preferred Shares, 3,561,936 to 0 shares (Indirect, See footnotes); Series B Preferred Shares, 1,611,008 to 0 shares (Indirect, See footnotes); Warrants (right to buy), 216,668 to 0 warrants (Indirect, See footnotes); Common Shares, 531,632 to 7,097,483 shares (Indirect, See footnotes)
Other Insiders: 2 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (7)
  1. F1. Reflects Common Shares of the Issuer purchased in the Issuer's initial public offering.
  2. F2. These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.
  3. F3. This report on Form 4 is jointly filed by OrbiMed Advisors and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
  4. F4. Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
  5. F5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
  6. F6. Reflects Common Shares withheld in connection with the Reporting Person's exercise of warrants.
  7. F7. The warrants are fully vested and exercisable.
IPO shares purchased 1,176,471 common shares OrbiMed Private Investments IX purchased them in the initial public offering on November 16, 2026.
IPO purchase price $17 per share Price for the common shares purchased on November 16, 2026.
Series A conversion 3,561,936 common shares Converted one-for-one immediately before the IPO closed on November 16, 2026.
Series B conversion 1,611,008 common shares Converted one-for-one immediately before the IPO closed on November 16, 2026.
Preferred-share conversion ratio 1-to-1 Series A and Series B preferred shares converted into common shares.
Warrants exercised 216,668 common shares Warrants exercised on November 16, 2026.
Warrant exercise price $0.02 per share Exercise price stated in U.S. dollars; the filing gives a CHF conversion rate of $1.2151 to CHF 1.00 as of October 30, 2026.
Shares for exercise-price payment or tax liability 232 common shares Withheld in connection with the warrant exercise on November 16, 2026.
initial public offering financial
"purchased in the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
Series A Preferred Share financial
"Each Series A Preferred Share and Series B Preferred Share"
Series A preferred share is an ownership stake issued in an early institutional funding round that gives its holders special rights compared with regular shares, such as priority to receive money if the company is sold or shuts down and often a fixed dividend or the option to convert into ordinary shares. For investors, these features act like a VIP pass—reducing downside risk, clarifying payout order, and influencing control and potential returns, so they shape how attractive and safe an investment is.
general partner financial
"GP IX is the general partner of OPI IX"
A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.
investment adviser regulatory
"registered investment adviser under the Investment Advisers Act of 1940"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.
beneficial ownership regulatory
"disclaims beneficial ownership of the securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many WWB shares did OrbiMed Private Investments IX buy in the IPO?

OrbiMed Private Investments IX, LP purchased 1,176,471 common shares at $17 per share in Windward Bio Group AG’s initial public offering on November 16, 2026.

How many WWB shares came from the preferred conversions and warrant exercise?

On November 16, 2026, the preferred shares converted into 3,561,936 common shares from Series A and 1,611,008 from Series B. OrbiMed Private Investments IX, LP also exercised warrants for 216,668 common shares at $0.02 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ORBIMED ADVISORS LLC

(Last)(First)(Middle)
601 LEXINGTON AVENUE
54TH FLOOR

(Street)
NEW YORK NEW YORK 10022

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
WINDWARD BIO GROUP AG [ WWB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares11/16/2026P1,176,471(1)A$171,708,103ISee footnotes(2)(3)
Common Shares11/16/2026C3,561,936A(4)5,270,039ISee footnotes(2)(3)
Common Shares11/16/2026C1,611,008A(4)6,881,047ISee footnotes(2)(3)
Common Shares11/16/2026M216,668A$0.02(5)7,097,715ISee footnotes(2)(3)
Common Shares11/16/2026F(6)232D$177,097,483ISee footnotes(2)(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A Preferred Shares(4)11/16/2026C3,561,936 (4) (4)Common Shares3,561,936$00ISee footnotes(2)(3)
Series B Preferred Shares(4)11/16/2026C1,611,008 (4) (4)Common Shares1,611,008$00ISee footnotes(2)(3)
Warrants (right to buy)$0.02(5)11/16/2026M216,668 (7)05/12/2036Common Shares216,668$00ISee footnotes(2)(3)
1. Name and Address of Reporting Person*
ORBIMED ADVISORS LLC

(Last)(First)(Middle)
601 LEXINGTON AVENUE
54TH FLOOR

(Street)
NEW YORK NEW YORK 10022

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
OrbiMed Capital GP IX LLC

(Last)(First)(Middle)
601 LEXINGTON AVENUE
54TH FLOOR

(Street)
NEW YORK NEW YORK 10022

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. Reflects Common Shares of the Issuer purchased in the Issuer's initial public offering.
2. These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.
3. This report on Form 4 is jointly filed by OrbiMed Advisors and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
4. Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
6. Reflects Common Shares withheld in connection with the Reporting Person's exercise of warrants.
7. The warrants are fully vested and exercisable.
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC11/18/2026
/s/ Carl L. Gordon, Member of OrbiMed Capital GP IX LLC11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading